All Blogs

Mar 26, 2025

Obesity is a chronic disease reaching alarming levels worldwide, leading to diabetes, cardiovascular disease, and metabolic disorders. It results from a mix of genetic, environmental, and lifestyle factors. Understanding what are the reasons for obesity—poor diet, inactivity, and hormonal imbalances—is crucial. Key...

Mar 25, 2025

Clover’s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study Clover Biopharmaceuticals, Ltd. has received FDA clearance for its Investigational New Drug (IND) application and has initiated a Phase I revaccination clinical trial for SCB-1019, its non-adjuvanted bivalent RSV prefusion-s...

Mar 31, 2025

MPS I treatment typically involves Hematopoietic Stem Cell Transplantation (HSCT), Enzyme Replacement Therapy (ERT), or a combination of both, along with supportive care such as pain management, anti-inflammatory medications, oxygen therapy, and surgery. While these MPS I treatments help manage symptoms and improve...

Mar 24, 2025

Mucopolysaccharidosis Type I (MPS I) is a rare genetic disorder caused by a deficiency of the enzyme α-L-iduronidase, leading to the buildup of complex sugars in the body. This progressive condition can impact multiple organs, causing skeletal abnormalities, vision, and hearing loss, and even cognitive decline.&nbs...

Mar 20, 2025

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in the Netherlands  On March 18, 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), received marketing authorization from the Medicines Evaluation Board (MEB) in t...

Mar 21, 2025

Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel, branded as ENCELTO. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurod...

Mar 28, 2025

Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach...

Mar 19, 2025

Mucopolysaccharidosis (MPS) is a group of rare genetic disorders affecting roughly 1 in 25,000 births, yet its impact is profound. Caused by enzyme deficiencies, MPS leads to the buildup of complex sugars in cells, resulting in progressive damage to the heart, bones, brain, and other organs. Symptoms can vary widel...

Mar 18, 2025

MDA Applauds FDA’s Expanded Approval of Soliris for Pediatric Generalized Myasthenia Gravis The Muscular Dystrophy Association (MDA) celebrates the FDA approval of an expanded indication for Alexion/AstraZeneca’s eculizumab (Soliris), now authorized for pediatric patients aged six and older with generalized myas...

Mar 17, 2025

The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. Novo Nordisk’s WEGOVY (semaglutide) and E...